Latest news with #CancerTreatment
The Sun
2 days ago
- Health
- The Sun
Thousands of men given ‘unnecessary' cancer treatment every year due to ‘wild west' guidelines
UP to 5,000 men every could avoid unnecessary cancer treatment if "outdated" guidelines reflected latest evidence, a charity has urged. Overtreatment can lead to side effects such as erectile dysfunction or incontinence, it warned. 1 Prostate cancer is a leading cause of cancer deaths in males in the UK, with around 55,000 new cases diagnosed every year. However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm. For men whose cancer is unlikely to progress, experts suggest close monitoring is the "best" option. However, out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a "wild west". Close monitoring involves blood tests and scans, known as active surveillance. Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored. However, it hasn't been updated since 2021, according to Prostate Cancer UK. A Freedom of information (FOI) request analysis by the charity found around one in four (24 per cent) of hospitals rely on Nice guidance alone to implement active surveillance. It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics. The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment. I thought I was drinking too much tea - but it was actually a deadly condition It also claims the outdated guidance is hindering a screening programme for prostate cancer. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: "To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven't caught up with the clinical evidence. "Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England. "Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men. "We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough." Current testing for prostate cancer The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions, including prostate cancer or an enlarged prostate. Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms. But there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment. Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: "Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime. "But Nice's outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams. What is prostate cancer? Prostate cancer affects a small, walnut shaped gland that sits underneath the bladder and surrounds the urethra - the tube carrying pee outside the body. It usually grows bigger as you get older. The prostate's main job is to help make semen – the fluid that carries sperm. Most men with early prostate cancer don't have any signs or symptoms - that's why it's important to know about your risk. Possible symptoms include: Difficulty starting to urinate or emptying your bladder A weak flow when you urinate A feeling that your bladder hasn't emptied properly Dribbling urine after you finish urinating Needing to urinate more often than usual, especially at night A sudden need to urinate – you may sometimes leak urine before you get to the toilet If you do notice changes in the way you urinate, this is more likely to be a sign of an enlarged prostate, which is very common and non-cancerous. But it's still a good idea to get it checked out. In the UK, about one in eight men will be diagnosed with prostate cancer in their lifetime. Some factors may mean you're more likely to get it. This includes: Getting older – it mainly affects men aged 50 or over Having a family history of prostate cancer Being Black If you have any of these risk factors or if you have any symptoms, speak to your GP. They can talk to you about your risk, and about the tests that are used to diagnose prostate cancer. Source: Prostate Cancer UK "This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects. "Programmes for active surveillance that are standardised and individualised to a man's risk factors have been tested and proven to work." The UK's National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out. A Nice spokesperson said: "We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes. "They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current. "We are updating our prostate cancer guidelines, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating." One in eight men will get prostate cancer The risk of developing prostate cancer depends on many factors, here are some of the facts about the disease and how many men it affects. One in eight men will get prostate cancer in their lifetime It is the fourth most common cancer worldwide, and the most common in men There are 55,000 new cases every year in the UK, and 1.4million globally Around 12,000 people lose their lives to prostate cancer annually in the UK and almost 400,000 around the world Prostate cancer accounts for 28 per cent of all new cancer cases in men in the UK, and 14 per cent of all new cancer cases in men and women combined Prostate cancer survival has tripled in the last 50 years in the UK More than three-quarters (78 per cent) of patients survive for 10 or more years About 490,000 men are living with and after prostate cancer in the UK It is most common in men aged 75 to 79 Since the early 1990s, cases have increased by 53 per cent in the UK Mortality rates are up 16 per cent since the early 1970s in the UK Incidence rates are projected to rise by 15 per cent in the UK between 2023 to 2025 and 2038 to 2040 Mortality rates are expected to fall five per cent in the UK over the same years
Globe and Mail
04-07-2025
- Health
- Globe and Mail
Chemotherapy Induced Nausea and Vomiting Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Chemotherapy Induced Nausea and Vomiting Pipeline Insight 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the Chemotherapy Induced Nausea and Vomiting pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Chemotherapy Induced Nausea and Vomiting Pipeline. Dive into DelveInsight's comprehensive report today! @ Chemotherapy Induced Nausea and Vomiting Pipeline Outlook Key Takeaways from the Chemotherapy Induced Nausea and Vomiting Pipeline Report In April 2025, Arbeitsgemeinschaft medikamentoese Tumortherapie conducted a phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose. DelveInsight's Chemotherapy Induced Nausea and Vomiting Pipeline report depicts a robust space with 4+ active players working to develop 6+ pipeline therapies for Chemotherapy Induced Nausea and Vomiting treatment. The leading Chemotherapy Induced Nausea and Vomiting Companies such as RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others. Promising Chemotherapy Induced Nausea and Vomiting Pipeline Therapies such as GW679769, Dexamethasone, Ondansetron Hydrochloride, Akynzeo, Fosaprepitant Dimeglumine, Intranasal granisetron, Rolapitant, Granisetron, and others. Stay ahead with the most recent pipeline outlook for Chemotherapy Induced Nausea and Vomiting. Get insights into clinical trials, emerging therapies, and leading companies with Chemotherapy Induced Nausea and Vomiting @ Chemotherapy Induced Nausea and Vomiting Treatment Drugs Chemotherapy Induced Nausea and Vomiting Emerging Drugs Profile RHB-102: RedHill Biopharma RHB-102 is a patent-protected, proprietary, once-daily, bimodal extended-release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist, targeting potential indications including oncology support, acute gastroenteritis and gastritis, and IBS-D at two dose strengths, 12mg and 24mg. RedHill Biopharma entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals for RHB-102 for gastroenteritis & gastritis, IBS-D and oncology support. Currently, the drug is in Phase III stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting. APD403: Acacia Pharma APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in Barhemsys®. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. APD403 has successfully completed one proof-of-concept and one Phase II dose-ranging study demonstrating it is well tolerated and effective at preventing acute and delayed CINV. Currently, the drug is in Phase II stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting. The Chemotherapy Induced Nausea and Vomiting Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Nausea and Vomiting with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Nausea and Vomiting Treatment. Chemotherapy Induced Nausea and Vomiting Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chemotherapy Induced Nausea and Vomiting Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Nausea and Vomiting market Explore groundbreaking therapies and clinical trials in the Chemotherapy Induced Nausea and Vomiting Pipeline. Access DelveInsight's detailed report now! @ New Chemotherapy Induced Nausea and Vomiting Drugs Chemotherapy Induced Nausea and Vomiting Companies RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others. Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Chemotherapy Induced Nausea and Vomiting Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Chemotherapy Induced Nausea and Vomiting Treatment. Learn about new drugs, Chemotherapy Induced Nausea and Vomiting Pipeline developments, and key companies with DelveInsight's expert analysis @ Chemotherapy Induced Nausea and Vomiting Market Drivers and Barriers Scope of the Chemotherapy Induced Nausea and Vomiting Pipeline Report Coverage- Global Chemotherapy Induced Nausea and Vomiting Companies- RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others. Chemotherapy Induced Nausea and Vomiting Pipeline Therapies- GW679769, Dexamethasone, Ondansetron Hydrochloride, Akynzeo, Fosaprepitant Dimeglumine, Intranasal granisetron, Rolapitant, Granisetron, and others. Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Chemotherapy Induced Nausea and Vomiting Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chemotherapy Induced Nausea and Vomiting Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Chemotherapy Induced Nausea and Vomiting: Overview Pipeline Therapeutics Therapeutic Assessment Chemotherapy Induced Nausea and Vomiting– DelveInsight's Analytical Perspective Late Stage Products (Phase III) RHB-102: RedHill Biopharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) APD403: Acacia Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Chemotherapy Induced Nausea and Vomiting Key Companies Chemotherapy Induced Nausea and Vomiting Key Products Chemotherapy Induced Nausea and Vomiting- Unmet Needs Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion Chemotherapy Induced Nausea and Vomiting Analyst Views Chemotherapy Induced Nausea and Vomiting Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Washington Post
17-06-2025
- Health
- Washington Post
Bujar Bukoshi, Kosovo independence leader, dies at 78
PRISTINA, Kosovo — Bujar Bukoshi, a former Kosovo independence leader who for years headed a self-proclaimed government-in-exile, died early Tuesday morning after a long illness, his family said. He was 78. He died in Kosovo after he was treated for cancer in Germany, where he was receiving financial support from the Albanian government, according to his family.
LBCI
19-05-2025
- Health
- LBCI
Former US President Biden diagnosed with 'aggressive' prostate cancer
Former U.S. President Joe Biden has been diagnosed with an "aggressive form" of prostate cancer that has spread to his bones, his office said in a statement on Sunday. Biden, 82, was diagnosed on Friday after experiencing urinary symptoms, and he and his family are reviewing treatment options with doctors, according to the statement. "While this represents a more aggressive form of the disease, the cancer appears to be hormone-sensitive which allows for effective management," his office said. Reuters
NHK
18-05-2025
- Health
- NHK
Former US President Biden diagnosed with prostate cancer
US media report that former US President Joe Biden has been diagnosed with prostate cancer. CNN and other media outlets report that a statement by his office says the cancer is aggressive but effective management is possible. The statement says Biden and his family are reviewing treatment options with his doctors.
